药品注册申请号:019050
申请类型:NDA (新药申请)
申请人:RISING
申请人全名:RISING PHARMA HOLDINGS INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 SUFENTA PRESERVATIVE FREE SUFENTANIL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Yes Yes AP 1984/05/04 1984/05/04 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/12/15 SUPPL-43(补充) Approval Labeling STANDARD
2019/10/07 SUPPL-37(补充) Approval Labeling STANDARD
2016/12/16 SUPPL-34(补充) Approval Labeling STANDARD
2014/03/20 SUPPL-32(补充) Approval Labeling STANDARD
2007/06/04 SUPPL-31(补充) Approval Labeling STANDARD
2001/08/27 SUPPL-25(补充) Approval Labeling STANDARD
1999/05/25 SUPPL-28(补充) Approval Manufacturing (CMC) PRIORITY
1998/05/26 SUPPL-27(补充) Approval Manufacturing (CMC) PRIORITY
1998/05/01 SUPPL-26(补充) Approval Manufacturing (CMC) PRIORITY
1997/08/12 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
1996/06/21 SUPPL-24(补充) Approval Labeling STANDARD
1995/02/22 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
1994/03/23 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
1994/03/23 SUPPL-19(补充) Approval Manufacturing (CMC) PRIORITY
1994/03/23 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1993/03/19 SUPPL-17(补充) Approval Efficacy
1992/11/10 SUPPL-21(补充) Approval Manufacturing (CMC) PRIORITY
1990/10/05 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1987/04/29 SUPPL-11(补充) Approval Manufacturing (CMC) PRIORITY
1986/11/14 SUPPL-10(补充) Approval Labeling
1986/11/14 SUPPL-9(补充) Approval Manufacturing (CMC) PRIORITY
1986/08/06 SUPPL-8(补充) Approval Manufacturing (CMC) PRIORITY
1986/06/20 SUPPL-4(补充) Approval Manufacturing (CMC) PRIORITY
1986/03/18 SUPPL-7(补充) Approval Manufacturing (CMC) PRIORITY
1986/03/18 SUPPL-6(补充) Approval Labeling
1985/08/21 SUPPL-3(补充) Approval Labeling
1985/08/21 SUPPL-2(补充) Approval Manufacturing (CMC) PRIORITY
1984/09/10 SUPPL-1(补充) Approval Manufacturing (CMC) PRIORITY
1984/05/04 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:SUFENTANIL CITRATE 剂型/给药途径:INJECTABLE;INJECTION 规格:EQ 0.05MG BASE/ML 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
019050 001 NDA SUFENTA PRESERVATIVE FREE SUFENTANIL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription Yes Yes AP 1984/05/04 RISING
074413 001 ANDA SUFENTANIL CITRATE SUFENTANIL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription No No AP 1995/12/15 HIKMA
074534 001 ANDA SUFENTANIL CITRATE SUFENTANIL CITRATE INJECTABLE;INJECTION EQ 0.05MG BASE/ML Prescription No No AP 1996/12/11 HOSPIRA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database